Dendritic cell vaccination in glioblastoma after fluorescence-guided resection

Table 1 Patients characteristics

Patient	Age(yr)	KPS(%)	RPA	Sex	MMSE score	Tumor volume (cc)	MGMT promoter	Tumor location	PFS (mo)	OS (mo)
1	69	70	5	M	28	111.8	Methylated	right frontal	19.5	27.0
2	73	70	5	M	27	34.0	Unmethylated	left temporal	3.1	9.1
3	50	80	5	F	26	12.9	Methylated	left temporal	3.2	> 36.0
4	67	60	5	F	28	68.3	Methylated	right frontal	16.1	27.4
5	71	90	4	F	30	44.8	Methylated	right frontal	20.3	> 32.0

KPS: Karnofsky performance status; MMSE: Mini mental state examination; MGMT: Status of O⁶-methylguanine-DNA methyltransferase; PFS: Progression free survival; OS: Overall survival; RPA: Recursive partitioning analysis.

Table 2 Summary of vaccine production data

	Number of producedvaccine doses	Number of administratedvaccine doses	Number of DC/dose		Amount tumor lysate (mg/mL)/107 iDC
			Range	Mean
UPN 1	16	11	10.00-10.00 × 106	10.00 × 106	67.4 (33.7 CP + 33.7 IP)
UPN 2	18	4	8.25-9.20 × 106	8.85 × 106	52.75 (CP)
UPN 3	4	4	2.30-6.80 × 106	3.40 × 106	75 (CP)
UPN 4	15	15	0.82-10.00 × 106	4.90 × 106	75 (37.5 CP + 37.5 IP) / 50 (20 CP + 30 IP)
UPN 5	16	12	1.00-10.00 × 106	4.89 × 106	75 (19 CP + 56 IP)

UPN: Unique patient number; DC: Dendritic cells; iDC: Immature dendritic cells; CP: Central portion; IP: Invasive portion.

Table 3 Summary of immune responses

Patient	Cellular response
	Proliferation			Cytokines
	DC	Tumor lysate		IFN-γ						TNF-α
		Centralportion	Invasiveportion	ELISA			ELISPOT			ELISA
				DC	Tumor lysate		DC	Tumor lysate		DC	Tumor lysate
					Central portion	Invasive portion		Central portion	Invasive portion		Central portion	Invasive portion
UPN 1	+	-	ND	+	-	ND	-	-	ND	-	-	ND
UPN 2	+	-	ND	+	-	ND	-	-	ND	-	-	ND
UPN 3	ND	-	ND	ND	-	ND	ND	-	ND	ND	-	ND
UPN 4	ND	-	-	ND	-	-	ND	-	-	ND	-	-
UPN 5	+	-	-	+	+	+	-	-	-	-	-	-

DC: Dendritic cells; ND: Not determined due to insufficient material. IFN: Interferon; TNF-α: Tumor necrosis factor α.